Old and Novel Therapies for Primary Biliary Cirrhosis

Abstract

Despite the presumed immunological pathogenesis of primary biliary cirrhosis, no clear or even harmful consequences resulted from some specific treatments addressed to modify the immunological condition. However, ursodeoxycholic acid (UDCA; 13–16 mg/kg/d) has clear favorable effects not only by improving biochemical cholestasis, but also by delaying the histological progression. Long -term treatment with UDCA is associated with excellent survival, free of transplantation in cases showing biochemical response at one year. In the remaining patients, data on the effect of fibrates, budesonide, or obeticholic acid are encouraging. Pruritus is usually managed using resins; further steps are needed in resistant cases with the use of rifampicin, naltrexone, sertraline, or invasive procedures such as albumin dialysis. Osteoporosis, which is highly prevalent in patients with deep and prolonged cholestasis, improves with bisphosphonates; current data indicate that both weekly alendronate and monthly ibandronate increase bone mass in patients with osteoporosis. Nutritional and fat-vitamin supplementation is also mandatory in patients with severe cholestasis.

Keywords

ursodeoxycholic acid - fibrates - budesonide - obeticholic acid - bisphosphonates - pruritus - osteoporosis

• References

• 1 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009; 51 (2) 237-267
• 2 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009; 50 (1) 291-308
• 3 Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 2006; 3 (6) 318-328
• 4 Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012; 36 (Suppl. 01) S3-S12
• 5 Poupon R, Chrétien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet 1987; 1 (8537) 834-836
• 6 Poupon RE, Balkau B, Eschwège E, Poupon R. UDCA-PBC Study Group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324 (22) 1548-1554
• 7 Heathcote EJ, Cauch-Dudek K, Walker V , et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994; 19 (5) 1149-1156
• 8 Lindor KD, Dickson ER, Baldus WP , et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994; 106 (5) 1284-1290
• 9 Combes B, Carithers Jr RL, Maddrey WC , et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995; 22 (3) 759-766
• 10 Parés A, Caballería L, Rodés J , et al; UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol 2000; 32 (4) 561-566
• 11 Poupon RE, Lindor KD, Parés A, Chazouillères O, Poupon R, Heathcote EJ. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003; 39 (1) 12-16
• 12 Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997; 113 (3) 884-890
• 13 Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354 (9184) 1053-1060
• 14 Gong Y, Huang Z, Christensen E, Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007; 102 (8) 1799-1807
• 15 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012; 12: CD000551
• 16 Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101 (7) 1529-1538
• 17 Angulo P, Dickson ER, Therneau TM , et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999; 30 (5) 830-835
• 18 Parés A, Caballería L, Rodés J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006; 130 (3) 715-720
• 19 Corpechot C, Abenavoli L, Rabahi N , et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008; 48 (3) 871-877
• 20 Kuiper EM, Hansen BE, de Vries RA , et al; Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136 (4) 1281-1287
• 21 Kumagi T, Guindi M, Fischer SE , et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010; 105 (10) 2186-2194
• 22 Corpechot C, Chazouillères O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011; 55 (6) 1361-1367
• 23 Zhang LN, Shi TY, Shi XH , et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology 2013; 58 (1) 264-272
• 24 Cavazza A, Caballería L, Floreani A , et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009; 50 (4) 1162-1168
• 25 Kuiper EM, Hansen BE, Adang RP , et al; Dutch PBC Study Group. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2010; 22 (12) 1495-1502
• 26 Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 2007; 46 (4) 1131-1137
• 27 Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000; 95 (1) 326-327
• 28 Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 2000; 95 (10) 2990-2992
• 29 Ohira H, Sato Y, Ueno T, Sata M. Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol 2002; 97 (8) 2147-2149
• 30 Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients?. J Gastroenterol 2003; 38 (6) 573-578
• 31 Akbar SM, Furukawa S, Nakanishi S, Abe M, Horiike N, Onji M. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J Gastroenterol 2005; 40 (2) 157-163
• 32 Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J Gastroenterol 2006; 41 (7) 686-692
• 33 Walker LJ, Newton J, Jones DE, Bassendine MF. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2009; 49 (1) 337-338 , author reply 338
• 34 Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol 2010; 44 (5) 371-373
• 35 Liberopoulos EN, Florentin M, Elisaf MS, Mikhailidis DP, Tsianos E. Fenofibrate in primary biliary cirrhosis: a pilot study. Open Cardiovasc Med J 2010; 4: 120-126
• 36 Levy C, Peter JA, Nelson DR , et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011; 33 (2) 235-242
• 37 Lens S, Leoz M, Nazal L, Bruguera M, Parés A. Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int 2014; 34 (2) 197-203
• 38 Honda A, Ikegami T, Nakamuta M , et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2013; 57 (5) 1931-1941
• 39 Matsumoto T, Miyazaki H, Nakahashi Y , et al. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res 2004; 30 (3) 125-136
• 40 Chianale J, Vollrath V, Wielandt AM , et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J 1996; 314 (Pt 3) 781-786
• 41 Leuschner M, Maier KP, Schlichting J , et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999; 117 (4) 918-925
• 42 Rautiainen H, Kärkkäinen P, Karvonen AL , et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology 2005; 41 (4) 747-752
• 43 Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 31 (2) 318-323
• 44 Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003; 38 (1) 196-202
• 45 Pellicciari R, Fiorucci S, Camaioni E , et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002; 45 (17) 3569-3572
• 46 Fiorucci S, Rizzo G, Donini A, Distrutti E, Santucci L. Targeting farnesoid X receptor for liver and metabolic disorders. Trends Mol Med 2007; 13 (7) 298-309
• 47 Pellicciari R, Costantino G, Fiorucci S. Farnesoid X receptor: from structure to potential clinical applications. J Med Chem 2005; 48 (17) 5383-5403
• 48 Trauner M, Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011; 140 (4) 1120-1125 , e1–e12
• 49 Fiorucci S, Antonelli E, Rizzo G , et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004; 127 (5) 1497-1512
• 50 Fiorucci S, Rizzo G, Antonelli E , et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005; 315 (1) 58-68
• 51 Mason A, Luketic VA, Lindor KD , et al. Farnesoid-X receptor agonists: a new class of drugs for the treatment of PBC? An international study evaluating the addition of obeticholic acid (int-747) to ursodeoxycholic acid (Abstract). Hepatology 2010; 52: 375A
• 52 Marschall HU, Luketic V, Lövgren-Sandblom A , et al. The farnesoid X receptor (FXR) agonist obeticholic acid (OCA) increases plasma FGF- 19 concen- trations and decreases bile acid synthesis in primary biliary cirrhosis (PBC) (Abstract). J Hepatol 2012; 56 (Suppl 2): S377
• 53 Kowdley KV, Jones D, Luketic V , et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC (Abstract). J Hepatol 2011; 54: S13
• 54 Myers RP, Swain MG, Lee SS, Shaheen AAM, Burak KW. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol 2013; 108 (6) 933-941
• 55 Hirschfield GM, Liu X, Xu C , et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360 (24) 2544-2555
• 56 Xu L, Shen Z, Guo L , et al. Does a betaretrovirus infection trigger primary biliary cirrhosis?. Proc Natl Acad Sci U S A 2003; 100 (14) 8454-8459
• 57 Mason AL, Farr GH, Xu L, Hubscher SG, Neuberger JM. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99 (12) 2348-2355
• 58 Mason AL, Lindor KD, Bacon BR , et al. Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008; 28 (7) 886-894
• 59 Hendrickse MT, Rigney E, Giaffer MH , et al. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 1999; 117 (2) 400-407
• 60 González-Koch A, Brahm J, Antezana C, Smok G, Cumsille MA. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol 1997; 27 (1) 143-149
• 61 Combes B, Emerson SS, Flye NL , et al. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology 2005; 42 (5) 1184-1193
• 62 Kaplan MM, Bonder A, Ruthazer R, Bonis PA. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid. Dig Dis Sci 2010; 55 (11) 3207-3217
• 63 Giljaca V, Poropat G, Stimac D, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev 2010; (5) CD004385
• 64 Bodenheimer Jr H, Schaffner F, Pezzullo J. Evaluation of colchicine therapy in primary biliary cirrhosis. Gastroenterology 1988; 95 (1) 124-129
• 65 Kaplan MM, Alling DW, Zimmerman HJ , et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med 1986; 315 (23) 1448-1454
• 66 Vuoristo M, Färkkilä M, Karvonen AL , et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 1995; 108 (5) 1470-1478
• 67 Warnes TW, Smith A, Lee FI, Haboubi NY, Johnson PJ, Hunt L. A controlled trial of colchicine in primary biliary cirrhosis. Trial design and preliminary report. J Hepatol 1987; 5 (1) 1-7
• 68 Zifroni A, Schaffner F. Long-term follow-up of patients with primary biliary cirrhosis on colchicine therapy. Hepatology 1991; 14 (6) 990-993
• 69 Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES. UDCA-PBC Study Group. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1996; 24 (5) 1098-1103
• 70 Gong Y, Gluud C. Colchicine for primary biliary cirrhosis: a Cochrane Hepato-Biliary Group systematic review of randomized clinical trials. Am J Gastroenterol 2005; 100 (8) 1876-1885
• 71 Wiesner RH, Ludwig J, Lindor KD , et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med 1990; 322 (20) 1419-1424
• 72 Lombard M, Portmann B, Neuberger J , et al. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology 1993; 104 (2) 519-526
• 73 Guañabens N, Parés A, Navasa M , et al. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. J Hepatol 1994; 21 (1) 24-28
• 74 Hoofnagle JH, Davis GL, Schafer DF , et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986; 91 (6) 1327-1334
• 75 Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 32 (5) 897-900
• 76 The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group. J Hepatol 1993; 17 (2) 227-235
• 77 McCormick PA, Scott F, Epstein O, Burroughs AK, Scheuer PJ, McIntyre N. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J Hepatol 1994; 21 (4) 496-499
• 78 Jones EA, ten Kate FJ, ter Borg F, Houben M, Reesink HW, Chamuleau RA. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999; 11 (10) 1165-1169
• 79 Leuschner M, Holtmeier J, Ackermann H, Leuschner U. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study. Eur J Gastroenterol Hepatol 2002; 14 (12) 1369-1376
• 80 Stojakovic T, Putz-Bankuti C, Fauler G , et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46 (3) 776-784
• 81 Cash WJ, O'Neill S, O'Donnell ME , et al. Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis. Liver Int 2013; 33 (8) 1166-1174
• 82 Invernizzi P, Alvaro D, Crosignani A, Gaudio E, Podda M. Tamoxifen in treatment of primary biliary cirrhosis. Hepatology 2004; 39 (4) 1175-1176
• 83 Phillips JR, Angulo P, Petterson T, Lindor KD. Fat-soluble vitamin levels in patients with primary biliary cirrhosis. Am J Gastroenterol 2001; 96 (9) 2745-2750
• 84 Pares A, Caballeria L, Deulofeu R, Rodés J. Circulating fat-soluble vitamins and antioxidants in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2005; 42 (4) 470A
• 85 Kaplan MM, Elta GH, Furie B, Sadowski JA, Russell RM. Fat-soluble vitamin nutriture in primary biliary cirrhosis. Gastroenterology 1988; 95 (3) 787-792
• 86 Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 1982; 83 (1 Pt 1) 97-102
• 87 Sokol RJ, Kim YS, Hoofnagle JH, Heubi JE, Jones EA, Balistreri WF. Intestinal malabsorption of vitamin E in primary biliary cirrhosis. Gastroenterology 1989; 96 (2 Pt 1) 479-486
• 88 Carey Jr JB, Williams G. Relief of the pruritus of jaundice with a bile-acid sequestering resin. JAMA 1961; 176: 432-435
• 89 Garbutt JT, Kenney TJ. Effect of cholestyramine on bile acid metabolism in normal man. J Clin Invest 1972; 51 (11) 2781-2789
• 90 Javitt NB. Timing of cholestyramine doses in cholestatic liver disease. N Engl J Med 1974; 290 (23) 1328-1329
• 91 Rust C, Sauter GH, Oswald M , et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest 2000; 30 (2) 135-139
• 92 Kuiper EM, van Erpecum KJ, Beuers U , et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 2010; 52 (4) 1334-1340
• 93 Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampin. Results of a double-blind, crossover, randomized trial. Gastroenterology 1988; 94 (2) 488-493
• 94 Bachs L, Parés A, Elena M, Piera C, Rodés J. Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet 1989; 1 (8638) 574-576
• 95 Podesta A, Lopez P, Terg R , et al. Treatment of pruritus of primary biliary cirrhosis with rifampin. Dig Dis Sci 1991; 36 (2) 216-220
• 96 Bachs L, Parés A, Elena M, Piera C, Rodés J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 1992; 102 (6) 2077-2080
• 97 Prince MI, Burt AD, Jones DEJ. Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 2002; 50 (3) 436-439
• 98 Tandon P, Rowe BH, Vandermeer B, Bain VG. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol 2007; 102 (7) 1528-1536
• 99 Khurana S, Singh P. Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int 2006; 26 (8) 943-948
• 100 Bloomer JR, Boyer JL. Phenobarbital effects in cholestatic liver diseases. Ann Intern Med 1975; 82 (3) 310-317
• 101 Wolfhagen FHJ, Sternieri E, Hop WCJ, Vitale G, Bertolotti M, Van Buuren HR. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology 1997; 113 (4) 1264-1269
• 102 Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002; 37 (6) 717-722
• 103 Bergasa NV, Schmitt JM, Talbot TL , et al. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology 1998; 27 (3) 679-684
• 104 Bergasa NV, Talbot TL, Alling DW , et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 1992; 102 (2) 544-549
• 105 Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98 (12) 2736-2741
• 106 Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ. Sertraline as a first-line treatment for cholestatic pruritus. Hepatology 2007; 45 (3) 666-674
• 107 Borgeat A, Wilder-Smith OH, Mentha G. Subhypnotic doses of propofol relieve pruritus associated with liver disease. Gastroenterology 1993; 104 (1) 244-247
• 108 Frezza M, Centini G, Cammareri G, Le Grazie C, Di Padova C. S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial. Hepatogastroenterology 1990; 37 (Suppl. 02) 122-125
• 109 Cerio R, Murphy GM, Sladen GE, MacDonald DM. A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis. Br J Dermatol 1987; 116 (2) 265-267
• 110 Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F. Role of plasmapheresis in primary biliary cirrhosis. Gut 1985; 26 (3) 291-294
• 111 Quintero E, Puig L, Parés A , et al. Utilidad del recambio plasmático intermitente en la cirrosis biliar primaria. Gastroenterol Hepatol 1986; 9 (7) 329-333
• 112 Alallam A, Barth D, Heathcote EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol 2008; 22 (5) 505-507
• 113 Pusl T, Denk GU, Parhofer KG, Beuers U. Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J Hepatol 2006; 45 (6) 887-891
• 114 Macia M, Avilés J, Navarro J, Morales S, García J. Efficacy of molecular adsorbent recirculating system for the treatment of intractable pruritus in cholestasis. Am J Med 2003; 114 (1) 62-64
• 115 Doria C, Mandalá L, Smith J , et al. Effect of molecular adsorbent recirculating system in hepatitis C virus-related intractable pruritus. Liver Transpl 2003; 9 (4) 437-443
• 116 Parés A, Cisneros L, Salmerón JM , et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99 (6) 1105-1110
• 117 Parés A, Herrera M, Avilés J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010; 53 (2) 307-312
• 118 Kremer AE, van Dijk R, Leckie P , et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 2012; 56 (4) 1391-1400
• 119 Beuers U, Gerken G, Pusl T. Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 2006; 44 (1) 280-281
• 120 Newton JL, Pairman J, Sutcliffe K, Wilton K, Jones DEJ. A predictive model for fatigue and its etiologic associations in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2008; 6 (2) 228-233
• 121 Newton JL, Gibson GJ, Tomlinson M, Wilton K, Jones D. Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence. Hepatology 2006; 44 (1) 91-98
• 122 Kaplan MM, Bonis PA. Modafinil for the treatment of fatigue in primary biliary cirrhosis. Ann Intern Med 2005; 143 (7) 546-547
• 123 Ian Gan S, de Jongh M, Kaplan MM. Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci 2009; 54 (10) 2242-2246
• 124 Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007; 25 (4) 471-476
• 125 Parés A, Guañabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin Liver Dis 2008; 12 (2) 407-424
• 126 Ruiz-Gaspà S, Guañabens N, Enjuanes A , et al. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur J Clin Invest 2010; 40 (1) 25-34
• 127 Ruiz-Gaspà S, Martinez-Ferrer A, Guañabens N , et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology 2011; 54 (6) 2104-2113
• 128 Dubreuil M, Ruiz-Gaspà S, Guañabens N , et al. Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. Liver Int 2013; 33 (7) 1029-1038
• 129 Guañabens N, Cerdá D, Monegal A , et al. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology 2010; 138 (7) 2348-2356
• 130 Guañabens N, Parés A, Monegal A , et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997; 113 (1) 219-224
• 131 Guañabens N, Parés A, Ros I , et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol 2003; 98 (10) 2268-2274
• 132 Wolfhagen FHJ, van Buuren HR, den Ouden JW , et al. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study. J Hepatol 1997; 26 (2) 325-330
• 133 Musialik J, Petelenz M, Gonciarz Z. Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year. Scand J Gastroenterol 2005; 40 (7) 873-874
• 134 Zein CO, Jorgensen RA, Clarke B , et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology 2005; 42 (4) 762-771
• 135 Guañabens N, Monegal A, Cerdá D , et al. Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology 2013; 58 (6) 2070-2078
• 136 Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?. Mayo Clin Proc 2002; 77 (10) 1031-1043
• 137 Treeprasertsuk S, Silveira MG, Petz JL, Lindor KD. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther 2011; 18 (5) 375-381
• 138 Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007; 5 (11) 1313-1315
• 139 Markus BH, Dickson ER, Grambsch PM , et al. Efficiency of liver transplantation in patients with primary biliary cirrhosis. N Engl J Med 1989; 320 (26) 1709-1713
• 140 Klion FM, Fabry TL, Palmer M, Schaffner F. Prediction of survival of patients with primary biliary cirrhosis. Examination of the Mayo Clinic model on a group of patients with known endpoint. Gastroenterology 1992; 102 (1) 310-313
• 141 Milkiewicz P. Liver transplantation in primary biliary cirrhosis. Clin Liver Dis 2008; 12 (2) 461-472 , xi